Pioneering Medical Innovations
Instylla, Inc. is a privately held company focused on delivering next-generation liquid embolics for interventional radiology, with initial clinical applications in interventional oncology and peripheral hemostasis.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology.
Acquired by Boston Scientific in 2018, Augmenix, Inc. developed and commercialized the SpaceOAR® System, a therapy used to reduce common and debilitating side effects that men may experience after receiving prostate cancer radiotherapy.
Ocular reported Q2 2026 results, confirming the AXPAXLI wet AMD NDA submission remains on track for Q4 2026 following a positive Type C meeting with the FDA.
Imperative Care launched the Ikon 24 Pro Guidewire, enhancing the Zoom Stroke System to support more efficient stroke procedures.
A new analysis of the SYMPHONY-PE Trial suggests early thrombectomy may improve key measures of heart recovery in intermediate-risk pulmonary embolism patients.
Jay Martin was appointed Chief Commercial Officer of Imperative Care.
Ocular reported Q1 2026 results, with a cash balance of $666.7 million and expected runway into 2028, following the positive SOL-1 readout.
Ocular announced a June 17 Investor Day in New York featuring company leadership and prominent retinal disease experts.